The following are the decisions for drugs considered by our drug advisory committee for inclusion to our formularies:
- Aripiprazole (PDF)
- Benzodiazepines (PDF)
- Botulinum Toxin A: Botox®,Botox Cosmetic®, Xeomin®
- Buprenorphine (Opioid use disorder)
- Buprenorphine (Treatment of chronic pain)(PDF)
- Calcitonin Gene-Related Peptide Monoclonal Antibodies in prevention of migraine
- Cannabinoid: Nabilone(PDF)
- Compounded Topical Analgesics (PDF)
- Corticosteroid injections (musculoskeletal conditions)*
- Desvenlafaxine (PDF)
- Diclofenac Sodium Solution 1.5%(PDF)
- Duloxetine (PDF)
- Escitalopram (PDF)
- HIV Post-Exposure Prophylaxis (PDF)
- Hypnotics: Zopiclone, Trazodone and Tryptophan(PDF
- Ketamine and esketamine
- Oxycodone/Naloxone Controlled Release(PDF)
- Paliperidone (PDF)
- Piroxicam (PDF)
- Pregabalin (PDF)
- Skeletal Muscle Relaxants (PDF)
- Spinal cord stimulator
- Tapentadol Controlled Release (PDF)
- Tramadol (PDF)
- Viscosupplements (PDF)
- Ziprasidone(PDF)
Updated: